Moderna新冠疫苗迟发性局部超敏反应病例系列
耶鲁纽黑文医院2021年1月20日至2月12日收治16例接种Moderna新冠疫苗后出现局部皮肤注射部位反应的患者,反应中位出现时间为接种后7天(范围2-12天),表现为瘙痒、疼痛、水肿性粉红色斑块;皮肤活检示以血管周围为主的淋巴细胞与嗜酸性粒细胞混合浸润,符合真皮超敏反应。多数首剂反应者第二剂后出现类似反应且出现更早,但反应自限,不伴严重疫苗不良事件,不是后续接种的禁忌证。
要点
- 迟发局部反应多在接种后7天(范围2-12天)出现,表现为瘙痒、疼痛、水肿性粉红色斑块
- 活检示血管周围淋巴细胞与嗜酸性粒细胞混合浸润,符合迟发型超敏反应
- 多数首剂反应者第二剂后出现类似反应且更早,但自限,不是接种禁忌
核心结论
- Moderna新冠疫苗的局部注射部位反应为迟发型超敏反应,自限且不伴严重疫苗不良事件,不是后续接种的禁忌证。
研究设计与样本
- 回顾性病例系列研究,于耶鲁纽黑文医院纳入16例转诊的局部皮肤注射部位反应患者,并分析1例皮肤活检标本的组织病理学表现。
主要发现
- 16例患者中位年龄38岁(范围25-89岁),13例(81%)为女性,14例自述为白人、2例为亚裔。
- 迟发局部皮肤反应在接种Moderna新冠疫苗后中位7天(范围2-12天)出现,位于注射部位或附近,为瘙痒、疼痛、水肿性粉红色斑块。
- 皮肤活检示以血管周围为主的轻度混合浸润,含淋巴细胞与嗜酸性粒细胞,符合真皮超敏反应。
- 16例中15例对第一剂有反应,其中11例在第二剂后出现类似局部注射部位反应,10例第二剂反应出现更早。
临床怎么用
- 临床识别接种后数日出现的局部瘙痒性水肿性斑块,结合病史考虑迟发型超敏反应。
- 向患者说明该反应自限、不伴严重不良事件,不是后续接种的禁忌证。
局限性
- 为单中心回顾性病例系列,样本量小(16例),仅1例进行皮肤活检,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In response to the coronavirus disease 2019 (COVID-19) pandemic, 2 mRNA vaccines (Pfizer-BioNTech and Moderna) received emergency use authorization from the US Food and Drug Administration in December 2020. Some patients in the US have developed delayed localized cutaneous vaccine reactions that have been dubbed "COVID arm." OBJECTIVE: To describe the course of localized cutaneous injection-site reactions to the Moderna COVID-19 vaccine, subsequent reactions to the second vaccine dose, and to characterize the findings of histopathologic examination of the reaction. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series study was performed at Yale New Haven Hospital, a tertiary medical center in New Haven, Connecticut, with 16 patients referred with localized cutaneous injection-site reactions from January 20 through February 12, 2021. MAIN OUTCOMES AND MEASURES: We collected each patient's demographic information, a brief relevant medical history, clinical course, and treatment (if any); and considered the findings of a histopathologic examination of 1 skin biopsy specimen. RESULTS: Of 16 patients (median [range] age, 38 [25-89] years; 13 [81%] women), 14 patients self-identified as White and 2 as Asian. The delayed localized cutaneous reactions developed in a median (range) of 7 (2-12) days after receiving the Moderna COVID-19 vaccine. These reactions occurred at or near the injection site and were described as pruritic, painful, and edematous pink plaques. None of the participants had received the Pfizer-BioNTech vaccine. Results of a skin biopsy specimen demonstrated a mild predominantly perivascular mixed infiltrate with lymphocytes and eosinophils, consistent with a dermal hypersensitivity reaction. Of participants who had a reaction to first vaccine dose (15 of 16 patients), most (11 patients) developed a similar localized injection-site reaction to the second vaccine dose; most (10 patients) also developed the second reaction sooner as compared with the first-dose reaction. CONCLUSIONS AND RELEVANCE: Clinical and histopathologic findings of this case series study indicate that the localized injection-site reactions to the Moderna COVID-19 vaccine are a delayed hypersensitivity reaction. These reactions may occur sooner after the second dose, but they are self-limited and not associated with serious vaccine adverse effects. In contrast to immediate hypersensitivity reactions (eg, anaphylaxis, urticaria), these delayed reactions (dubbed "COVID arm") are not a contraindication to subsequent vaccination.
引用
- Johnston MS, Galan A, Watsky KL, et al. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. JAMA Dermatol. 2021. PMID: 33978670. doi:10.1001/jamadermatol.2021.1214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。